Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.
Mau-Ern PohSoon Hin HowGwo Fuang HoYong Kek PangHarissa H HasbullahLye Mun ThoIbtisam Muhamad NorBee Chiu LimKean Fatt HoMuthukkumaran ThiagarajanAzlina SamsudinAzza OmarChoo Khoon OngSing Yang SoonJustin Yu Kuan TanMuhammad Adil Zainal AbidinPublished in: Cancer management and research (2023)
Patients on ALK inhibitors had longer median OS and significantly longer TOT compared to chemotherapy, suggesting long-term benefit.